Search
243 results found for “C-S4CPR-2402 Examsfragen 🍊 C-S4CPR-2402 Pruefungssimulationen 🆑 C-S4CPR-2402 Schulungsunterlagen 🌲 Suchen Sie jetzt auf ➠ www.itzert.com 🠰 nach [ C-S4CPR-2402 ] um den kostenlosen Download zu erhalten 🥠C-S4CPR-2402 Testing Engine”
Bio-Techne® and Carterra® initiate a clinical research collaboration for COVID-19 variant analysis
https://carterra-bio.com/news/bio-techne-and-carterra-initiate-a-clinical-research-collaboration-for-covid-19-variant-analysis/…For additional information, please visit www.carterra-bio.com. Media Inquiries: Bio-Techne Contact: David Clair Senior Director, Investor Relations & Corporate Development david.clair@bio-techne.com +1-612-656-4416 Carterra Inc Contact: Cheri Salazar Senior Marketing Manager csalazar@carterra-bio.com…
Immunity Monitoring of COVID-19 Patients Using a SARS-CoV-2 Label-free Assay
https://carterra-bio.com/news/carterra-announces-successful-immunity-monitoring-of-covid-19-patients-using-a-sars-cov-2-label-free-assay/…give researchers the most comprehensive insight into serum immune reactivity, specificity, and epitope binding. “The pandemic has forced the scientific community to find ways to discover and develop therapeutics and…
Carterra Announces Multiple Sales of its New LSA™ Array SPR Instrument for Comprehensive Monoclonal Antibody Characterization
https://carterra-bio.com/news/carterra-announces-multiple-sales-of-its-new-lsa-array-spr-instrument-for-comprehensive-monoclonal-antibody-characterization/…epitope mapping. Combined with Carterra’s unique data analysis and visualization software, the platform delivers the highest throughput and data quality available for mAb characterization, while using minimal sample. info@carterra-bio.com www.carterra-bio.com…
Generation of T cells with reduced off-target cross-reactivities by engineering co-signalling receptors
https://carterra-bio.com/resources/generation-of-t-cells-with-reduced-off-target-cross-reactivities-by-engineering-co-signalling-receptors/Jose Cabezas-Caballero, Anna Huhn, Mikhail A. Kutuzov, Violaine Andre, Alina Shomuradova, P. Anton van der Merwe, Omer Dushek Abstract Adoptive T cell therapy using T cells engineered with novel…
Free Symposia: Unlocking High-Throughput Biology
https://carterra-bio.com/free-symposia-on-high-throughput-drug-discovery/Free Symposia: Unlocking High-Throughput Biology…
La Jolla Institute for Immunology Acquires LSA Platform
https://carterra-bio.com/news/la-jolla-institute-for-immunology-acquires-lsa-platform/…in a complex matrix is also now best-in-class. “We’re proud to see the benefit of Carterra’s LSA platform being brought to bear for global good,” says Tim Germann, Chief Commercial…
Product Overview
https://carterra-bio.com/product-overview/…platforms can transform your label-free characterization workflow allowing screening and characterization, for both large and small molecules, in a single step. Check them out! LSA LSAXT Ultra Download the brochure…
Cell Reports: Bivalent intra-spike binding provides durability against emergent Omicron lineages: Results from a global consortium
https://carterra-bio.com/resources/bivalent-intra-spike-binding-provides-durability-against-emergent-omicron-lineages-results-from-a-global-consortium/…Troup, S. Moses Dennison, Kan Li, Michael Alpert, Charles C. Bailey, Sharon Benzeno, Jody L. Bonnevier, Jin-Qiu Chen, Charm Chen, Hyeseon Cho, Peter D. Crompton, Vincent Dussupt, Kevin C. Entzminger,…
Science: LY-CoV555, a Rapidly Isolated Potent Neutralizing Antibody, Provides Protection in a Non-Human Primate Model of SARS-CoV-2 Infection
https://carterra-bio.com/resources/ly-cov555-a-rapidly-isolated-potent-neutralizing-antibody-provides-protection-in-a-non-human-primate-model-of-sars-cov-2-infection/…through study Day 6 following viral inoculation. This antibody has entered clinical testing and is being evaluated across a spectrum of COVID-19 indications, including prevention and treatment. Introduction The global…
Platform for Next Generation Antibody Discovery
https://carterra-bio.com/news/carterra-closes-financing-round-for-continued-growth-of-the-lsa-platform-for-next-generation-antibody-discovery/…founded in 2001 and based in San Francisco and San Diego, CA, invests in innovative commercial stage life science, medical technology and healthcare companies. For more information please visit www.telegraphhillpartners.com….